Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Development of Collagen-Based 3D Matrix for Gastrointestinal Tract-Derived Organoid Culture.

Jee JH, Lee DH, Ko J, Hahn S, Jeong SY, Kim HK, Park E, Choi SY, Jeong S, Lee JW, Cho HJ, Kwon MS, Yoo J.

Stem Cells Int. 2019 Jun 13;2019:8472712. doi: 10.1155/2019/8472712. eCollection 2019.

2.

In vivo evaluation of scaffolds compatible for colonoid engraftments onto injured mouse colon epithelium.

Jee J, Jeong SY, Kim HK, Choi SY, Jeong S, Lee J, Ko JS, Kim MS, Kwon MS, Yoo J.

FASEB J. 2019 Jun 18:fj201802692RR. doi: 10.1096/fj.201802692RR. [Epub ahead of print]

PMID:
31211931
3.

Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A.

Im EJ, Lee CH, Moon PG, Rangaswamy GG, Lee B, Lee JM, Lee JC, Jee JG, Bae JS, Kwon TK, Kang KW, Jeong MS, Lee JE, Jung HS, Ro HJ, Jun S, Kang W, Seo SY, Cho YE, Song BJ, Baek MC.

Nat Commun. 2019 Mar 27;10(1):1387. doi: 10.1038/s41467-019-09387-4.

4.

The Protective Effects of Increasing Serum Uric Acid Level on Development of Metabolic Syndrome.

Yu TY, Jin SM, Jee JH, Bae JC, Lee MK, Kim JH.

Diabetes Metab J. 2019 Feb 21. doi: 10.4093/dmj.2018.0079. [Epub ahead of print]

5.

Directing GDNF-mediated neuronal signaling with proactively programmable cell-surface saccharide-free glycosaminoglycan mimetics.

Cai S, Lukamto DH, Toh JKC, Huber RG, Bond PJ, Jee JE, Lim TC, Liu P, Chen L, Qu QV, Lee SS, Lee SG.

Chem Commun (Camb). 2019 Jan 24;55(9):1259-1262. doi: 10.1039/c8cc09253b.

PMID:
30632548
6.

Leucine-rich repeat-containing G-protein coupled receptor 5 enriched organoids under chemically-defined growth conditions.

Hahn S, Kim MS, Choi SY, Jeong S, Jee J, Kim HK, Jeong SY, Shin H, Kim HS, Park JS, Yoo J.

Biochem Biophys Res Commun. 2019 Jan 8;508(2):430-439. doi: 10.1016/j.bbrc.2018.11.003. Epub 2018 Nov 28.

PMID:
30503340
7.

Corrigendum: 7-Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir.

Ziegler RE, Desai BK, Jee JA, Gupton BF, Roper TD, Jamison TF.

Angew Chem Int Ed Engl. 2018 Nov 12;57(46):14969. doi: 10.1002/anie.201809594. Epub 2018 Sep 16. No abstract available.

PMID:
30398024
8.

Properties of Heparinoids Premixed with Tumor-Derived Extracellular Vesicles.

Manandhar S, Park J, Kothandan VK, Lee J, Alam F, Jee JP, Hwang J, Byun Y, Hwang SR.

Bioconjug Chem. 2018 Nov 21;29(11):3757-3767. doi: 10.1021/acs.bioconjchem.8b00637. Epub 2018 Nov 5.

PMID:
30372043
9.

Preparation and Characterization of Celecoxib Nanosuspension Using Bead Milling.

Kim HI, Jee JP, Kim ST, Kang D, Kim YC, Kim HC, Park SY, Lee HM, Cho KH, Kim DY, Choi SU, Jang DJ.

J Nanosci Nanotechnol. 2019 Feb 1;19(2):1184-1187. doi: 10.1166/jnn.2019.15917.

PMID:
30360230
10.

Utility of Serum Albumin for Predicting Incident Metabolic Syndrome according to Hyperuricemia.

Lee YB, Jun JE, Lee SE, Ahn J, Kim G, Jee JH, Bae JC, Jin SM, Kim JH.

Diabetes Metab J. 2018 Dec;42(6):529-537. doi: 10.4093/dmj.2018.0012. Epub 2018 Sep 28.

11.

LINCS L1000 dataset-based repositioning of CGP-60474 as a highly potent anti-endotoxemic agent.

Han HW, Hahn S, Jeong HY, Jee JH, Nam MO, Kim HK, Lee DH, Lee SY, Choi DK, Yu JH, Min SH, Yoo J.

Sci Rep. 2018 Oct 8;8(1):14969. doi: 10.1038/s41598-018-33039-0.

12.

Development and Evaluation of a Reconstitutable Dry Suspension to Improve the Dissolution and Oral Absorption of Poorly Water-Soluble Celecoxib.

Kim HI, Park SY, Park SJ, Lee J, Cho KH, Jee JP, Kim HC, Maeng HJ, Jang DJ.

Pharmaceutics. 2018 Aug 29;10(3). pii: E140. doi: 10.3390/pharmaceutics10030140.

13.

7-Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir.

Ziegler RE, Desai BK, Jee JA, Gupton BF, Roper TD, Jamison TF.

Angew Chem Int Ed Engl. 2018 Jun 11;57(24):7181-7185. doi: 10.1002/anie.201802256. Epub 2018 May 14. Erratum in: Angew Chem Int Ed Engl. 2018 Nov 12;57(46):14969.

14.

Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A 7-Year Longitudinal Study.

Kim G, Lee SE, Lee YB, Jun JE, Ahn J, Bae JC, Jin SM, Hur KY, Jee JH, Lee MK, Kim JH.

Hepatology. 2018 Nov;68(5):1755-1768. doi: 10.1002/hep.30049. Epub 2018 Oct 14.

PMID:
29679374
15.

Intravenous Delivery of Xenon Incorporated in Thermosensitive Nano-Emulsions for Anesthesia.

Kim A, Jang DJ, Shin HC, Jee U, Jee JP.

J Nanosci Nanotechnol. 2017 Apr;17(4):2784-790.

PMID:
29667807
16.

The inhibitory potential of Broussochalcone A for the human cytochrome P450 2J2 isoform and its anti-cancer effects via FOXO3 activation.

Park SH, Lee J, Shon JC, Phuc NM, Jee JG, Liu KH.

Phytomedicine. 2018 Mar 15;42:199-206. doi: 10.1016/j.phymed.2018.03.032. Epub 2018 Mar 19.

PMID:
29655687
17.

4-Hydroxynonenal-induced GPR109A (HCA2 receptor) activation elicits bipolar responses, Gαi -mediated anti-inflammatory effects and Gβγ -mediated cell death.

Gautam J, Banskota S, Shah S, Jee JG, Kwon E, Wang Y, Kim DY, Chang HW, Kim JA.

Br J Pharmacol. 2018 Jul;175(13):2581-2598. doi: 10.1111/bph.14174. Epub 2018 May 22.

18.

Effects of a small molecule R-spondin-1 substitute RS-246204 on a mouse intestinal organoid culture.

Nam MO, Hahn S, Jee JH, Hwang TS, Yoon H, Lee DH, Kwon MS, Yoo J.

Oncotarget. 2017 Dec 26;9(5):6356-6368. doi: 10.18632/oncotarget.23721. eCollection 2018 Jan 19.

19.

Improved Dissolution and Oral Bioavailability of Celecoxib by a Dry Elixir System.

Cho KH, Jee JP, Yang DA, Kim ST, Kang D, Kim DY, Sim T, Park SY, Kim K, Jang DJ.

J Nanosci Nanotechnol. 2018 Feb 1;18(2):1482-1486. doi: 10.1166/jnn.2018.14885.

PMID:
29448619
20.

Removing Control of Cyclodextrin-Drug Complexes Using High Affinity Molecule.

Kim YH, Kim ST, Jee JP, Kim DY, Kang D, Kim K, Park SY, Sim T, Cho KH, Jang DJ.

J Nanosci Nanotechnol. 2018 Feb 1;18(2):898-901. doi: 10.1166/jnn.2018.14877.

PMID:
29448513
21.

Increase in relative skeletal muscle mass over time and its inverse association with metabolic syndrome development: a 7-year retrospective cohort study.

Kim G, Lee SE, Jun JE, Lee YB, Ahn J, Bae JC, Jin SM, Hur KY, Jee JH, Lee MK, Kim JH.

Cardiovasc Diabetol. 2018 Feb 5;17(1):23. doi: 10.1186/s12933-018-0659-2.

22.

Structural ensemble-based docking simulation and biophysical studies discovered new inhibitors of Hsp90 N-terminal domain.

Kim HH, Hyun JS, Choi J, Choi KE, Jee JG, Park SJ.

Sci Rep. 2018 Jan 10;8(1):368. doi: 10.1038/s41598-017-18332-8.

23.

A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots.

Seo J, Al-Hilal TA, Jee JG, Kim YL, Kim HJ, Lee BH, Kim S, Kim IS.

Nanomedicine. 2018 Apr;14(3):633-642. doi: 10.1016/j.nano.2017.12.022. Epub 2018 Jan 6.

PMID:
29309907
24.

Thiopurine Drugs Repositioned as Tyrosinase Inhibitors.

Choi J, Lee YM, Jee JG.

Int J Mol Sci. 2017 Dec 28;19(1). pii: E77. doi: 10.3390/ijms19010077.

25.

Interaction between human angiogenin and the p53 TAD2 domain and its implication for inhibitor discovery.

Yeo KJ, Jee JG, Hwang E, Kim EH, Jeon YH, Cheong HK.

FEBS Lett. 2017 Dec;591(23):3916-3925. doi: 10.1002/1873-3468.12899. Epub 2017 Nov 14.

26.

Functionalized ZnO Nanoparticles with Gallic Acid for Antioxidant and Antibacterial Activity against Methicillin-Resistant S. aureus.

Lee J, Choi KH, Min J, Kim HJ, Jee JP, Park BJ.

Nanomaterials (Basel). 2017 Nov 2;7(11). pii: E365. doi: 10.3390/nano7110365.

27.

Antithrombotic properties of JJ1, a potent and novel thrombin inhibitor.

Lee W, Lee S, Choi J, Park JH, Kim KM, Jee JG, Bae JS.

Sci Rep. 2017 Nov 1;7(1):14862. doi: 10.1038/s41598-017-13868-1.

28.

Serum calcium changes and risk of type 2 diabetes mellitus in Asian population.

Suh S, Bae JC, Jin SM, Jee JH, Park MK, Kim DK, Kim JH.

Diabetes Res Clin Pract. 2017 Nov;133:109-114. doi: 10.1016/j.diabres.2017.08.022. Epub 2017 Sep 5.

PMID:
28934667
29.

Cxcr2 signaling and the microbiome suppress inflammation, bile duct injury, and the phenotype of experimental biliary atresia.

Jee J, Mourya R, Shivakumar P, Fei L, Wagner M, Bezerra JA.

PLoS One. 2017 Aug 1;12(8):e0182089. doi: 10.1371/journal.pone.0182089. eCollection 2017.

30.

Hormetic effect of triiodothyronine in metabolically healthy obese persons.

Jun JE, Kim TH, Lee SE, Lee YB, Jee JH, Bae JC, Jin SM, Hur KY, Kim JH, Kim SW, Chung JH, Min YK, Lee MK.

Endocrine. 2017 Sep;57(3):418-427. doi: 10.1007/s12020-017-1363-9. Epub 2017 Jul 19.

PMID:
28726184
31.

A novel solid self-nanoemulsifying drug delivery system (S-SNEDDS) for improved stability and oral bioavailability of an oily drug, 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol.

Kim KS, Yang ES, Kim DS, Kim DW, Yoo HH, Yong CS, Youn YS, Oh KT, Jee JP, Kim JO, Jin SG, Choi HG.

Drug Deliv. 2017 Nov;24(1):1018-1025. doi: 10.1080/10717544.2017.1344335.

PMID:
28675315
32.

Ligand-Mediated Folding of the OmpA Periplasmic Domain from Acinetobacter baumannii.

Mushtaq AU, Park JS, Bae SH, Kim HY, Yeo KJ, Hwang E, Lee KY, Jee JG, Cheong HK, Jeon YH.

Biophys J. 2017 May 23;112(10):2089-2098. doi: 10.1016/j.bpj.2017.04.015.

33.

Increase in serum albumin concentration is associated with prediabetes development and progression to overt diabetes independently of metabolic syndrome.

Jun JE, Lee SE, Lee YB, Jee JH, Bae JC, Jin SM, Hur KY, Lee MK, Kim JH.

PLoS One. 2017 Apr 21;12(4):e0176209. doi: 10.1371/journal.pone.0176209. eCollection 2017.

34.

Metabolically healthy obesity and the risk for subclinical atherosclerosis.

Kim TJ, Shin HY, Chang Y, Kang M, Jee J, Choi YH, Ahn HS, Ahn SH, Son HJ, Ryu S.

Atherosclerosis. 2017 Jul;262:191-197. doi: 10.1016/j.atherosclerosis.2017.03.035. Epub 2017 Mar 28.

PMID:
28385392
35.

Comparative feasibility study on retrofitting ballast water treatment system for a bulk carrier.

Jee J, Lee S.

Mar Pollut Bull. 2017 Jun 30;119(2):17-22. doi: 10.1016/j.marpolbul.2017.03.041. Epub 2017 Mar 24.

PMID:
28347495
36.

Decline in lung function rather than baseline lung function is associated with the development of metabolic syndrome: A six-year longitudinal study.

Kim SK, Bae JC, Baek JH, Jee JH, Hur KY, Lee MK, Kim JH.

PLoS One. 2017 Mar 27;12(3):e0174228. doi: 10.1371/journal.pone.0174228. eCollection 2017.

37.

Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins.

Martin TL, Jee J, Kim E, Steiner HE, Cormet-Boyaka E, Boyaka PN.

Vaccine. 2017 Apr 25;35(18):2511-2519. doi: 10.1016/j.vaccine.2017.02.064. Epub 2017 Mar 24.

38.

Cefdinir Solid Dispersion Composed of Hydrophilic Polymers with Enhanced Solubility, Dissolution, and Bioavailability in Rats.

Cho HJ, Jee JP, Kang JY, Shin DY, Choi HG, Maeng HJ, Cho KH.

Molecules. 2017 Feb 13;22(2). pii: E280. doi: 10.3390/molecules22020280.

39.

Serum 25-hydroxyvitamin D cutoffs for functional bone measures in postmenopausal osteoporosis.

Lee DY, Jee JH, Cho YY, Jang JY, Yu TY, Kim TH, Hong YJ, Hong WJ, Jin SM, Hur KY, Kim JH, Kim SW, Chung JH, Lee MK, Min YK.

Osteoporos Int. 2017 Apr;28(4):1377-1384. doi: 10.1007/s00198-016-3892-0. Epub 2017 Feb 10.

PMID:
28188454
40.

TSH increment and the risk of incident type 2 diabetes mellitus in euthyroid subjects.

Jun JE, Jin SM, Jee JH, Bae JC, Hur KY, Lee MK, Kim SW, Kim JH.

Endocrine. 2017 Mar;55(3):944-953. doi: 10.1007/s12020-016-1221-1. Epub 2017 Jan 2.

PMID:
28042645
41.

Serum Calcium and the Risk of Incident Metabolic Syndrome: A 4.3-Year Retrospective Longitudinal Study.

Baek JH, Jin SM, Bae JC, Jee JH, Yu TY, Kim SK, Hur KY, Lee MK, Kim JH.

Diabetes Metab J. 2017 Feb;41(1):60-68. doi: 10.4093/dmj.2017.41.1.60. Epub 2016 Dec 26.

42.

Increment of serum bilirubin as an independent marker predicting new-onset type 2 diabetes mellitus in a Korean population.

Lee SE, Lee YB, Jun JE, Jin SM, Jee JH, Bae JC, Kim JH.

Nutr Metab Cardiovasc Dis. 2017 Mar;27(3):234-240. doi: 10.1016/j.numecd.2016.10.003. Epub 2016 Oct 22.

PMID:
27989511
43.

Change in Serum Bilirubin Level as a Predictor of Incident Metabolic Syndrome.

Lee YB, Lee SE, Jun JE, Jee JH, Bae JC, Jin SM, Kim JH.

PLoS One. 2016 Dec 9;11(12):e0168253. doi: 10.1371/journal.pone.0168253. eCollection 2016.

44.

Association Between Changes in Thyroid Hormones and Incident Type 2 Diabetes: A Seven-Year Longitudinal Study.

Jun JE, Jee JH, Bae JC, Jin SM, Hur KY, Lee MK, Kim TH, Kim SW, Kim JH.

Thyroid. 2017 Jan;27(1):29-38. doi: 10.1089/thy.2016.0171. Epub 2016 Dec 9.

PMID:
27809684
45.

Change in serum albumin concentration is inversely and independently associated with risk of incident metabolic syndrome.

Jin SM, Hong YJ, Jee JH, Bae JC, Hur KY, Lee MK, Kim JH.

Metabolism. 2016 Nov;65(11):1629-1635. doi: 10.1016/j.metabol.2016.08.006. Epub 2016 Aug 24.

PMID:
27733251
46.

The effect of TSH change per year on the risk of incident chronic kidney disease in euthyroid subjects.

Lee DY, Jee JH, Jun JE, Kim TH, Jin SM, Hur KY, Kim SW, Chung JH, Lee MK, Kim JH.

Endocrine. 2017 Feb;55(2):503-512. doi: 10.1007/s12020-016-1138-8. Epub 2016 Oct 5.

PMID:
27709472
47.

A Target-Based Whole Cell Screen Approach To Identify Potential Inhibitors of Mycobacterium tuberculosis Signal Peptidase.

Bonnett SA, Ollinger J, Chandrasekera S, Florio S, O'Malley T, Files M, Jee JA, Ahn J, Casey A, Ovechkina Y, Roberts D, Korkegian A, Parish T.

ACS Infect Dis. 2016 Dec 9;2(12):893-902. Epub 2016 Sep 19.

48.

Delayed heart rate recovery after exercise as a risk factor of incident type 2 diabetes mellitus after adjusting for glycometabolic parameters in men.

Yu TY, Jee JH, Bae JC, Hong WJ, Jin SM, Kim JH, Lee MK.

Int J Cardiol. 2016 Oct 15;221:17-22. doi: 10.1016/j.ijcard.2016.06.149. Epub 2016 Jun 26.

PMID:
27400291
49.

LDL-C/apoB and HDL-C/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort.

Bae JC, Han JM, Kwon S, Jee JH, Yu TY, Lee MK, Kim JH.

Atherosclerosis. 2016 Aug;251:170-176. doi: 10.1016/j.atherosclerosis.2016.06.029. Epub 2016 Jun 16.

PMID:
27341533
50.

An efficient strategy to enhance binding affinity and specificity of a known isozyme inhibitor.

Jee JE, Lim J, Ong YS, Oon J, Gao L, Choi HS, Lee SS.

Org Biomol Chem. 2016 Jul 12;14(28):6833-9. doi: 10.1039/c6ob01104g.

Supplemental Content

Support Center